The Phenotypic Spectrum of Patients with PHARC Syndrome Due to Variants in ABHD12: An Ophthalmic Perspective

This study investigated the phenotypic spectrum of PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and early-onset cataract) syndrome caused by biallelic variants in the ABHD12 gene. A total of 15 patients from 12 different families were included, with a mean age of 36.7 years (standard deviation [SD] ± 11.0; range from 17.5 to 53.9) at the most recent examination. The presence and onset of neurological, audiological and ophthalmic symptoms were variable, with no evident order of symptom appearance. The mean best-corrected visual acuity was 1.1 logMAR (SD ± 0.9; range from 0.1 to 2.8; equivalent to 20/250 Snellen) and showed a trend of progressive decline. Different types of cataract were observed in 13 out of 15 patients (87%), which also included congenital forms of cataract. Fundus examination revealed macular involvement in all patients, ranging from alterations of the retinal pigment epithelium to macular atrophy. Intraretinal spicular hyperpigmentation was observed in 7 out of 15 patients (47%). From an ophthalmic perspective, clinical manifestations in patients with PHARC demonstrate variability with regard to their onset and severity. Given the variable nature of PHARC, an early multidisciplinary assessment is recommended to assess disease severity.

[1]  Ramiro S. Maldonado,et al.  Expanding the clinical phenotype in patients with disease causing variants associated with atypical Usher syndrome , 2021, Ophthalmic genetics.

[2]  Yingying Hong,et al.  A Review of Complicated Cataract in Retinitis Pigmentosa: Pathogenesis and Cataract Surgery , 2020, Journal of ophthalmology.

[3]  R. Guymer,et al.  Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials , 2020, Progress in Retinal and Eye Research.

[4]  P. Artal,et al.  In vivo SS-OCT imaging of crystalline lens sutures. , 2020, Biomedical optics express.

[5]  S. Klebe,et al.  Genotype‐phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome , 2020, Journal of the peripheral nervous system : JPNS.

[6]  J. Wijnholds,et al.  RPGR-Associated Dystrophies: Clinical, Genetic, and Histopathological Features , 2020, International journal of molecular sciences.

[7]  N. Oluonye,et al.  Congenital cataract: a guide to genetic and clinical management , 2020, Therapeutic advances in rare disease.

[8]  W. Hauswirth,et al.  Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  J. Clayton-Smith,et al.  Functional and in-silico interrogation of rare genomic variants impacting RNA splicing for the diagnosis of genomic disorders , 2019, bioRxiv.

[10]  Kathleen A. Marshall,et al.  Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. , 2019, Ophthalmology.

[11]  T. Langmann,et al.  Microglia in Retinal Degeneration , 2019, Front. Immunol..

[12]  Hyeon-Cheol Lee,et al.  Lipid-metabolizing serine hydrolases in the mammalian central nervous system: endocannabinoids and beyond. , 2019, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids.

[13]  Siddhesh S. Kamat,et al.  Biochemical characterization of the PHARC-associated serine hydrolase ABHD12 reveals its preference for very-long-chain lipids , 2018, The Journal of Biological Chemistry.

[14]  B. J. Klevering,et al.  Non-syndromic retinitis pigmentosa , 2018, Progress in Retinal and Eye Research.

[15]  S. Tsang,et al.  Rates of Bone Spicule Pigment Appearance in Patients With Retinitis Pigmentosa Sine Pigmento. , 2018, American journal of ophthalmology.

[16]  C. Espinós,et al.  Phenotypical features of two patients diagnosed with PHARC syndrome and carriers of a new homozygous mutation in the ABHD12 gene , 2018, Journal of the Neurological Sciences.

[17]  Alaa M Althubaiti,et al.  Information bias in health research: definition, pitfalls, and adjustment methods , 2016, Journal of multidisciplinary healthcare.

[18]  M. McKenna,et al.  Anti CD163+, Iba1+, and CD68+ Cells in the Adult Human Inner Ear: Normal Distribution of an Unappreciated Class of Macrophages/Microglia and Implications for Inflammatory Otopathology in Humans , 2016, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[19]  Y. Murakami,et al.  Factors affecting visual acuity after cataract surgery in patients with retinitis pigmentosa. , 2015, Ophthalmology.

[20]  T. Hashimoto,et al.  Novel ABHD12 Mutations in PHARC Patients , 2015, The Annals of otology, rhinology, and laryngology.

[21]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[22]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[23]  T. Bird,et al.  Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay , 2014, Nature chemical biology.

[24]  B. J. Klevering,et al.  Exome sequencing extends the phenotypic spectrum for ABHD12 mutations: from syndromic to nonsyndromic retinal degeneration. , 2014, Ophthalmology.

[25]  H. Mefford,et al.  Two Novel Mutations in ABHD12: Expansion of the Mutation Spectrum in PHARC and Assessment of Their Functional Effects , 2013, Human mutation.

[26]  G. Siuzdak,et al.  ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC , 2013, Proceedings of the National Academy of Sciences.

[27]  Carsten Bergmann,et al.  Targeted next-generation sequencing identifies a homozygous nonsense mutation in ABHD12, the gene underlying PHARC, in a family clinically diagnosed with Usher syndrome type 3 , 2012, Orphanet Journal of Rare Diseases.

[28]  J. Laitinen,et al.  The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors , 2012, Acta physiologica.

[29]  Donald C. Hood,et al.  ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition) , 2012, Documenta Ophthalmologica.

[30]  N. Drouot,et al.  Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. , 2010, American journal of human genetics.

[31]  J. Majewski,et al.  A novel Refsum-like disorder that maps to chromosome 20 , 2009, Neurology.

[32]  E. Mardis.  The impact of next-generation sequencing technology on genetics. , 2008, Trends in genetics : TIG.

[33]  B. Cravatt,et al.  A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2‐Arachidonoylglycerol , 2007, Chemistry & biology.

[34]  S. Tuft,et al.  Outcome of cataract surgery in patients with retinitis pigmentosa , 2001, The British journal of ophthalmology.

[35]  G. Fishman,et al.  Visual acuity impairment in patients with retinitis pigmentosa. , 1996, Ophthalmology.

[36]  A. Milam,et al.  Histopathology of bone spicule pigmentation in retinitis pigmentosa. , 1995, Ophthalmology.

[37]  G. Fishman,et al.  Prevalence of posterior subcapsular lens opacities in patients with retinitis pigmentosa. , 1985, The British journal of ophthalmology.